Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10900MR)

This product GTTS-WQ10900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10900MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7915MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ133MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ9065MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ15567MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ4909MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ6264MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15715MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ3536MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW